Graeme Bell
Independent DirectorMr. Graeme Bell is Independent Director of Averin Capital Acquisition Corp. from February 19, 2026. Mr. Graeme Bell is Chief Financial Officer of Owkin, Inc. from July 2025. He was Interim Chief Executive Officer of Valo Health, Inc. from January 16, 2024 until November 2024. Mr. Bell had been Chief Financial Officer of Valo Health, Inc. since August 2020 until January 16, 2024 and served as its Executive Vice President. He was a Treasurer at Valo Health, Inc. until January 16, 2024. He was Director of Cytoimmune Therapeutics, Inc. since March 2023 until 2024. Mr. Bell has been Founder & Principal of ValueCycle, LLC since June 2020 and Director of Pennsylvania Interscholastic Cycling League since October 2019. He also serves as a member of the Board of Directors of Mindstate Design Labs Inc. since December 2025, as a member of the Board of Advisors of Symbiotix Health Ltd. since March 2025 and as a University -Appointed Mentor at Loughborough University Science and Enterprise Park since September 2024. He served as a member of the Board of Advisors of Raphael Labs Ltd. from June 2020 to May 2025. Mr. Bell served as Executive Vice President and Chief Financial Officer (CFO) of Tmunity Therapeutics, Inc. since September 2018 until June 2020. Mr. Bell was Chief Financial Officer and Executive Vice President of Intellia Therapeutics Inc. from December 2016 to August 3, 2018 and was its Principal Accounting Officer until August 3, 2018. Mr. Bell served as the Chief Financial Officer and Executive Vice President of Anacor Pharmaceuticals, Inc. from June 01, 2015 to December 2016. Mr. Bell has also served on the boards or advisory boards of Airmed LLC, Auravax LLC and ImmunoGenesis Inc. He led the finance, human resources, IT and facilities functions. Prior to Anacor, he spent more than 20 years at Merck & Co, Inc. where he held numerous finance and accounting senior-level positions including: Chief Financial Officer of U.S. operations, Controller, Global Pharmaceutical Franchises, Chief Financial Officer United Kingdom subsidiary and head of investor relations. He has more than 20 years of global financial experience in the pharmaceutical industry. He experienced pharmaceutical executive whose two decades in financial leadership roles at Merck & Co. Inc. He has extensive business development, strategic, operational and investor relations experience, practical expertise resourcing product launches, as well as exceptional financial leadership skills. He joined Anacor from Merck & Co. Inc. where he served since 2010 as its Vice President, Country Chief Financial Officer of U.S. Human Health, responsible for the financial oversight and support of Merck & Co. Inc.’s U.S. pharmaceutical and vaccine business. Prior to his most recent role, he served in a number of positions of increasing responsibility at Merck & Co. Inc. including as its Global Pharmaceutical Franchises Controller from 2009 to 2010, Country Chief Financial Officer of U.K. from 2008 to 2009 and Global Head of Investor Relations from 2004 to 2008. Mr. Bell received his M.B.A. in Finance and Marketing from Durham University (United Kingdom) from 1992 to 1993 and is a Fellow of the Chartered Institute of Management Accountants (CIMA) from 1987 to 1992.
Positions
- Company NameAverin Capital Acquisition Corp.Stock CodeACAAPositionIndependent DirectorRelated Securities
